p53 Mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential

Journal of Urology

Volumn 161, Issue 1, 1999, Pages 304-308

  Navone, Nora M ^a   Labate, Michael E ^b   Troncoso, Patricia ^b   Pisters, Louis L ^b   Conti, Claudio J ^b   Von Eschenbach, Andrew C ^b   Logothetis, Christopher J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

Androgen independent; Bone metastases; P53; Prostate cancer

Indexed keywords

AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN TISSUE; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0032876470     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62136-0     Document Type: Article

References (31)

1. Wingo, P. A., Tong, T. and Bolden, S.: Cancer statistics. CA Cancer J. Clin., 45: 8, 1995.
2. Catalona, W. J.: Management of cancer of the prostate. N. Engl. J. Med., 331: 996, 1994.
3. Gittes, R. F.: Carcinoma of the prostate. N. Engl. J. Med., 324: 236, 1991.
4. Koivisto, P., Hyytinen, E., Palmberg, C., Tammela, T., Visakorpi, T., Isola, J. and Kallioniemi, O. P.: Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am. J. Pathol., 147: 1608, 1995.
5. Tilley, W. D., Buchanan, G., Hickey, T. E. and Bentel, J. M.: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res., 2: 277, 1996.
6. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N. and Balk, S. P.: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393, 1995.
7. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H. and Hittmair, A.: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068, 1995.
8. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C. J., Chung, L. W., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
9. McDonnell, T. J., Navone, N. M., Troncoso, P., Pisters, L., Conti, C. J., von Eschenbach, A. C., Brisbay, S. and Logothetis, C. J.: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol., 157: 569, 1997.
10. Raffo, A. J., Perlman, H., Chen, M. W., Day, M. L., Streitman, J. S. and Buttyan, R.: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438, 1995.
11. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I. and Isaacs, W. B.: An uncertain role of p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814, 1996.
12. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, L. P., Nichols, W. W., von Eschenbach, A. C. and Conti, C. J.: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
13. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z. F., Fuks, Z. and Cordon-Cardo, C.: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarci-noma. J. Urol., 151: 1276, 1994.
14. Eastham, J. A., Stapleton, A. M. F., Gousse, A. E., Timme, T. L., Yang, G., Slawin, K. M., Wheeler, T. M., Scardino, P. T. and Thompson, T. C.: Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res., 1: 1111, 1995.
15. Hall, M. C., Navone, N. M., Troncoso, P., Pollack, A., Zagars, G. K., von Eschenbach, A. C., Conti, C. J. and Chung, L. W.: Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology, 45: 470, 1995.
16. Visakorpi, T., Kallioniemi, O. P., Keikkinen, A., Koivula, T. and Isola, J.: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883, 1992.
17. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. and Alfred, D. C.: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369, 1993.
18. Dinjens, W.: N., van der Weiden, M. M., Schroeder, F. H., Bosnian, F. T. and Trapman, J.: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer, 56: 630, 1994.
19. Voeller, H. J., Sugars, L. Y., Pretlow, T. and Gelman, T.: p53 oncogene mutations in human prostate specimens. J. Urol., 151: 492, 1994.
20. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W. and Srivastava, S.: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol., 154: 414, 1995.
21. Catalona, W. J. and Scott, W. W.: Carcinoma of the prostate. In: Campbell's Urology, 5th ed. Edited by P. C. Walsh, R. F. Gittes and A. D. Perlmutter. Philadelphia: W. S. Saunders Co., pp. 1463-1534, 1986.
22. Gleason, D.: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by Tannenbaum. Philadelphia: Lea and Febiger, pp. 171-197, 1977.
23. Orita, M., Susuki, Y., Sekiya, T. and Hayashi, K.: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5: 874, 1989.
24. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C.: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855, 1994.
25. Chang, F., Syrjanen, S. and Syrjanen, K.: Implications of p53 tumor supressor-gene in clinical oncology. J. Clin. Oncol., 13: 1009, 1996.
26. Liebermann, D. A., Hoffman, B. and Steinman, A.: Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene, 11: 199, 1995.
27. Heidenberg, H. B., Bauer, J. J., McLeod, D. G., Moul, J. W. and Srivastava. S.: The role of the p53 tumor supressor gene in prostate cancer: a possible biomarker? Urology, 48: 971, 1996.
28. Mirchandani, D., Zheng, J., Miller, G. J., Ghosh, A. K., Shibata, D. K., Cote, R. J. and Roy-Burman, P.: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am. J. Pathol., 147: 92, 1995.
29. Yang, G., Stapleton, A. M. F., Wheeler, T. M., Truong, L. D., Timme, T. L., Scardino, T. L. and Thompson, T. C.: Clustered p53 immunostaining - a novel pattern associated with prostate cancer progression. Clin. Cancer Res., 2: 399, 1996.
30. Bauer, J. J., Sesterhenn, I. A., Mostofi, K. F., McLeod, D. G., Srivastava, S. and Moul, J. W.: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., 1: 1295, 1995.
31. Stapleton, A. M. F., Timme, T. L., Gousse, A. E., Li, Q-F., Tobon, A. A., Kattan, M. W., Slawin, K. M., Wheeler, T. M., Scardino, T. L. and Thompson, T. C.: Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin. Cancer Res., 3: 1389, 1997.